Verisante Technology, Inc. is committed to helping save lives through the commercialization of innovative systems for the detection of cancer. The Company has licensed a technology developed by the BC Cancer Agency for in vivo, real-time, non-invasive skin measurements. This platform technology may also be applied to detection systems for other types of cancer.

The Company's initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. Verisante's AuraTM (for skin cancer detection) has now been featured by more than a dozen major media outlets, including CNN, Reader's Digest, and the National Post. AuraTM was also awarded a “Best of What's New Award” by Popular Science magazine for 2011, while Verisante's Core™ (for lung cancer detection) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

Verisante was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada, and also named as the year's top ranking Technology and Life Sciences Company on the TSX Venture 50. The Company has also been named a finalist for the BC Technology Industry Association's 2012 Technology Impact Awards in the category of “Most Promising Pre-Commercial Technology”.